Supply and Co-Marketing Agreement Provides Biotechnology and
Pharmaceutical Customers with a Total Solution for Drug Candidate
Detection and Validation
WALTHAM, Mass.--(Business Wire)--
PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences
and Photonics, and Cerep SA (Eurolist: Cerep), a leading provider of
drug candidate screening and profiling technologies, today announced
the signing of a supply and co-marketing agreement to deliver custom
drug discovery services. Under the terms of the agreement, PerkinElmer
will exclusively market Cerep's target screening and profiling
services to its customers, and the companies will jointly promote
PerkinElmer's assay technologies and Cerep services to the drug
discovery market.
"This agreement represents the latest step in our strategy to
build the most comprehensive offering in biochemical and cellular
screening for drug discovery," said Robert F. Friel, president and
chief executive officer, PerkinElmer, Inc. "Our customers will benefit
from direct access to Cerep's expertise in high throughput screening
and profiling services, while PerkinElmer will be able to extend the
reach of our leading assay technologies and assay development services
into key drug discovery markets."
"Cerep is committed to providing the highest quality services in
drug discovery and drug development and we are pleased to work with an
established leader of drug discovery technologies to further
strengthen our offerings," said Thierry Jean, chairman and chief
executive officer, Cerep. "This agreement with PerkinElmer enables us
to support our customers' complete drug discovery needs, from assay
design to target screening and profiling, by adding a range of
enabling assay technologies to our drug screening and profiling
services."
This agreement provides PerkinElmer customers with an option to
work with a single vendor throughout the entire drug discovery
process. Cerep customers will now have access to several key assay
development and detection platforms from PerkinElmer's Bio-discovery
business, including AlphaScreen(R), AlphaLISA(TM), LANCE(R), and
LANCE(R) Ultra(TM) for G protein-coupled receptor (GPCR) and kinase
assay development.
GPCRs and protein kinases represent a wide range of therapeutic
targets in areas including cancer, central nervous system disorders,
cardiac dysfunction and diabetes, making them among the most important
areas of study in today's pharmaceutical and biotech laboratories.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow, revenue growth
and other financial results, developments relating to our customers
and end-markets, and plans concerning business development
opportunities. Words such as "believes," "intends," "anticipates,"
"plans," "expects," "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's
current assumptions and expectations and no assurances can be given
that our assumptions or expectations will prove to be correct. A
number of important risk factors could cause actual results to differ
materially from the results described, implied or projected in any
forward-looking statements. These factors include, without limitation:
(1) our failure to introduce new products in a timely manner; (2) our
ability to execute acquisitions and license technologies, or to
successfully integrate acquired businesses and licensed technologies
into our existing business or to make them profitable; (3) our failure
to protect adequately our intellectual property; (4) the loss of any
of our licenses or licensed rights; (5) our ability to compete
effectively; (6) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(7) our ability to produce an adequate quantity of products to meet
our customers' demands; (8) our failure to maintain compliance with
applicable government regulations; (9) regulatory changes; (10) our
failure to comply with health care industry regulations; (11)
economic, political and other risks associated with foreign
operations; (12) our ability to retain key personnel; (13)
restrictions in our credit agreements; (14) our ability to realize the
full value of our intangible assets; and (15) other factors which we
describe under the caption "Risk Factors" in our most recent annual
report on Form 10-K and in our most recent quarterly report on Form
10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the
quality of life. The Company reported revenues of $1.8 billion in
2007, has 9,100 employees serving customers in more than 150
countries, and is a component of the S&P 500 Index. Additional
information is available through www.perkinelmer.com or
1-877-PKI-NYSE.
Cerep's mission is to provide pharmaceutical companies with high
quality services in drug discovery and drug development. Cerep
provides, both in Europe and in the United States, solutions allowing
faster and cost effective drug discovery by identifying at early
stages the most promising drug candidates as well as eliminating those
compounds likely to fail in development.
Additional information is available through www.cerep.com
Investor Relations:
PerkinElmer, Inc.
Michael A. Lawless, 781-663-5659
or
Media Contact:
PerkinElmer, Inc.
Stephanie Wasco, 781-663-5701
or
Cerep
Thierry Jean, Chairman & CEO
Michele Arnoe, Global Head, Business Development
Tel. +33 (0)1 45 64 44 60
fincom@cerep.fr
Copyright Business Wire 2008
